Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00189475 · ClinicalTrials.gov registry record · Phase 4

Evaluate the Potential of Montelukast to Prevent Nasal Symptomatology During Colds

A Phase 4 study of Upper Respiratory Infection, sponsored by Deborah Gentile.

Completed
Registry status
Phase 4
Development phase
84
Enrollment target
1
Study location

NCT00189475 is a Phase 4 study of Upper Respiratory Infection that has completed, run by Deborah Gentile. The registered enrollment target is 84 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00189475, a Phase 4 study of Upper Respiratory Infection, has completed, sponsored by Deborah Gentile.

COMPLETED
Registry status
Phase 4
Development phase
84 participants
Enrollment target
1
Study location

Study Summary

Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for the treatment of viral-induced upper respiratory infection in healthy adults aged 18-50 years.

Interventions

  • DRUG Placebo
  • DRUG Montelukast

Study Locations (1)

Pennsylvania

  • Allegheny General Hospital - Pittsburgh

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2003-10
Est. Completion 2007-07
Phase Phase 4

Sponsor

Deborah Gentile

3 total trials

What the Registry Record Tells You About NCT00189475

The ClinicalTrials.gov registry entry for NCT00189475 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Deborah Gentile, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Upper Respiratory Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00189475 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00189475 about?

NCT00189475 is a clinical study titled "Evaluate the Potential of Montelukast to Prevent Nasal Symptomatology During Colds". Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for the treatment of viral-induced upper respiratory infection in healthy adults aged 18-50 years.

What is the current status of trial NCT00189475?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 84 participants. The study started on 2003-10. Estimated completion is 2007-07.

What conditions does trial NCT00189475 study?

This clinical trial studies the following conditions: Upper Respiratory Infection.

What interventions are being tested in trial NCT00189475?

The interventions under investigation include: Placebo (DRUG), Montelukast (DRUG).

Who is sponsoring clinical trial NCT00189475?

This trial is sponsored by Deborah Gentile, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00189475 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Upper Respiratory Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.